Isabella C. Glitza - Concepedia

Author

Isabella C. Glitza

The University of Texas MD Anderson Cancer Center

Also Known As

Celeste Lebbe, I. C. Glitza, I. Glitza, I.C. Glitza, Isabella C Glitza, Isabella C. Glitza, Isabella Glitza, White, Richard M.

316

Publications

13.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Baylor College of Medicine Parker Institute for Cancer Immunotherapy Harvard University Yale University

About

Isabella C. Glitza is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	23	4K
2	Health Sciences	5	5	863
3	Public Health	3	3	873
4	Allergy	2	2	69
5	Biostatistics	1	1	11

Isabella C. Glitza

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients Vancheswaran Gopalakrishnan, Christine N. Spencer, Luigi Nezi, Science	2017	4.4K
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Weiyi Peng, Jie Qing Chen, Chengwen Liu, Cancer Discovery	2015	1.5K
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Pei-Ling Chen, Whijae Roh, Alexandre Reuben, Cancer Discovery	2016	971
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance Whijae Roh, Pei-Ling Chen, Alexandre Reuben, Science Translational Medicine T-regulatory CellImmunologyPathologyImmune Checkpoint BlockadeImmunotherapy	2017	902
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan, Science NutritionDysbiosisGut BacteriaImmunologyDietary Fibre	2021	804
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma Rodabe N. Amaria, Sangeetha M. Reddy, Hussein A. Tawbi, Nature Medicine MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2018	797
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade Miles C. Andrews, Connie P.M. Duong, Vancheswaran Gopalakrishnan, Nature Medicine DysbiosisHealth SciencesMucosal ImmunologyPd-1 BlockadeMedicine	2021	388
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases Grant M. Fischer, Ali Jalali, David A. Kircher, Cancer Discovery	2019	334
Neoadjuvant relatlimab and nivolumab in resectable melanoma Rodabe N. Amaria, Michael A. Postow, Elizabeth M. Burton, Nature	2022	312
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff, The Lancet Oncology Surgical OncologyMedicineCancer ManagementMelanomaClinical Trials	2018	285

Page 1